The first description of chemotherapy-induced heart failure  
(Stage C) was published in 1967. There has been a therapeutic  
evolution in oncological treatment since then, as shown by  
the fact that, as of 2005, the survival rate exceeded that of  
mortality. This has resulted in a new epidemiological problem  
for these survivors, since at least 30% of them will show some  
degree of cardiotoxicity, which can occur up to decades  
after the end of the chemotherapy. Moreover, cardiovascular  
mortality is already considered the second most common  
cause of death, second only to cancer.3-5  

The classically accepted definition for cardiotoxicity during  
treatment was proposed in 2014, which described it as an  
absolute decrease in left ventricular (LV) ejection fraction  
of 10 percentage points to values below 53%, with its re-evaluation  
being recommended after 2 to 3 weeks. Additionally, the  
subclinical lesion is based on the relative decrease in global LV  
longitudinal strain by 15% in relation to the baseline. The major  
concern is that systolic dysfunction can lead to a therapeutic  
dose adjustment, less effective alternative therapy regimens, or,  
in the worst-case scenario, to chemotherapy discontinuation.  

In 2016, the European Society of Cardiology reviewed  
the definition of chemotherapy-induced cardiotoxicity and  
extended it to include any structural or functional alteration  
in the heart and circulation, whether during cancer treatment,  
post-treatment or late post-treatment.7 That requires a  
conceptual amplification of the rationale in the cardiac  
monitoring of the oncological patient, which was previously  
restricted to an arbitrary ejection fraction value, without  
respecting the individualization of the patient’s hemodynamic  
parameters, gender and age, which all influence ejection  
fraction calculation.  

It is important to note that the ejection fraction calculated  
by Simpson's two-dimensional method does not evaluate  
alterations in LV segmental contractility corresponding to 25%  
of its segments, considering the segmentation of 16 segments:8  
the mid-basal portion of the inferolateral wall (two segments)  
and the mid-basal portion of the anteroseptal wall (two segments) are not analyzed, and this technical limitation is overcome by the three-dimensional echocardiogram.9  

Considering this problem and a pragmatic observation of  
those who follow this patient population, the relevance of the  
isolated LV segmental alterations as chemotherapy-induced  
toxicity and its prognostic impact has been considered.  

A case-control study published in 2017 showed that the  
segmental motility alteration in the interventricular septum was  
associated with a reduction in left ventricular performance,  
despite the presence of a preserved ejection fraction.10  

The study published in this issue evaluated a prospective  
cohort of breast cancer patients and showed the incremental  
value of altered LV segmental motility in predicting  
cardiotoxicity induced by anthracyclines and/or trastuzumab.11  
It is noteworthy that a high cardiotoxicity rate (16.1%) was  
observed in a population of which 35% were hypertensive;  
22% were smokers; 19% were dyslipidemic and 7% were  
diabetics. There is no description in the present study of the  
doxorubicin and trastuzumab doses used in the treatment,  
the interval between examinations was variable between the  
groups, and whether the appearance of segmental motility  
alterations could be related to obstructive coronary disease,  
since several patients had risk factors.  

Weberpals et al. in 201812 described a cohort of 347,476  
breast cancer patients exposed to chemotherapy or  
radiotherapy during a follow-up of more than 10 years and  
who showed no increase in cardiac mortality when compared  
to the general population.12  

Another relevant piece of information not described in the  
text was whether there was a decrease of more than 15%  
of the LV global longitudinal strain (GLS) in patients who  
showed segmental contractility alterations. It is already well  
established that LV GLS is capable of predicting the reduction  
in LV ejection fraction13 and, in some institutions, it is indicated  
to initiate cardioprotection drugs even in the presence of a  
preserved ejection fraction. It is interesting to note that the  
segmental motility alterations described in 14% of the patients  
in the aforementioned article (interventricular septum, inferior  
and inferolateral) are the same regions that physiologically  
show coronary flow reduction.14  

The proposed concept as one of the pathophysiological  
possibilities for the preferential segmental involvement described  
in Chagas’ disease is that the terminal circulation - between  
the anterior descending coronary artery and the posterior  
descending artery (LV apex) and the terminal circulation  
between the right coronary artery and the left circumflex artery  
(the basal inferolateral segment) - contributes to the Chagasic  
lesion in these regions. Thus, it is likely that the aggressive  
agent (chemotherapy agent, or the Trypanosoma cruzi, for instance)  
would show a slower clearing in these regions, increasing the  
time of cardiomyocyte deleterious exposure.
Undeniably, chemotherapy-induced cardiotoxicity is multifactorial, but perhaps such a pathophysiological hypothesis might have a clinical consequence when endothelial and coronary vasomotor functions are improved prior to exposure to chemotherapy (statins, vasodilators, beta-blockers). Of the 14 patients with altered segmental contractility, 50% of cases consisted of atypical septal movement. Nevertheless, changes in septal movement constitute a nonspecific finding, as there is an extensive range of etiologies that alter septal motility, such as conditions that cause LV volume or pressure increase; primary involvement of the cardiomyocyte (cardiomyopathies); electric conduction changes; post-surgical status; pericardial disease; congenital cardiomyopathies; post-systolic shortening and interventricular mass, and, therefore, one should be cautious in attributing such finding to cardiotoxicity, despite its plausibility.

An alternative that would help to understand the findings would be to expose the evolution of the LV GLS fall between the different groups and to analyze if there was any similarity between the findings of segmental alterations and the parametric arrangement of LV GLS. Although the importance of myocardial deformation segmental alterations is still debatable, there are studies that have shown the incremental role of this type of analysis.16,17

The present cohort described in the article mentioned in this editorial does not clarify how the groups were divided, making it difficult to understand how the statistical calculation was carried out. It would be interesting to have a univariate and a multivariate analysis of the factors that contributed to the ejection fraction decrease (systolic blood pressure, radiotherapy dose and site, chemotherapy dose, relative decrease in LV strain, initial absolute strain values, etc.). Moreover, a more detailed analysis of ventricular volumes and diastolic function would allow a better understanding of ventricular remodeling. Similarly, another limitation would be the inclusion of post-systolic shortening at the maximum strain peak, without considering the cardiac cycle phase.

Regardless of the exposed limitations, the article shows the relevance of a limited discussed finding, the alterations in LV segmental motility during chemotherapy treatment, which may be secondary to the disease, the treatment, or the decompensation of an underlying disease.

References

1. Tan C, Tasaka H, Yu KP, Murphy ML, Karnofsky DA. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967;20(3):333-53.

2. DeVita VT Jr, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366(23):2207-14.

3. Yeh ET, Bickford CL. Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol. 2009;53(24):2231-47.

4. Aleman BM, Moser EC, Nuwer J, Suter TM, Maraldo MV, Specht L, et al. Cardiovascular disease after cancer therapy: EJC Suppl. 2014;12(1):18-28.

5. Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016;66(4):223-47.

6. Lang RM, Badano LP, Mor-Avi V, Albiero D, Chen J, Cram J, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28(1):1-39.e14.

7. Zhang KW, Finkelstein BS, Galati G, Narayan HK, Upshaw J, Narayan V, et al. Abnormalities in 3-Dimensional Left Ventricular Mechanics With Anthracycline Chemotherapy Are Associated With Systolic and Diastolic Dysfunction. JACC Cardiovasc Imaging. 2018;11(8):1059-68.

8. Okuma H, Noto N, Tanikawa S, Kanezawa K, Hirai M, Shimozawa K, et al. Impact of persistent left ventricular regional wall motion abnormalities in childhood cancer survivors after anthracycline therapy: Assessment of global left ventricular myocardial performance by 3D speckle-tracking echocardiography. J Cardiol. 2017;70(4):396-401.

9. Barros, MV. Left ventricular regional wall motion abnormality is a strong predictor of cardiotoxicity in breast cancer patients undergoing chemotherapy. Arq Bras Cardiol. 2019; 112(1):50-56.

10. Weberpals J, Jansen L, Müller OJ, Brenner H. Long-term heart-specific mortality among 347 476 breast cancer patients treated with radiotherapy or chemotherapy: a registry-based cohort study. Eur Heart J. 2018;39(43):3896-903.

11. Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review. J Am Coll Cardiol. 2014;63(25 Pt A):2751-68.

12. Changchitawatee P, Kaufmann PA, Rimoldi O, Camici PG. Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans. Cardiovasc Res. 2001;50(1):151-61.

13. Dwivedi A, Axel L. Abnormal Motion Patterns of the Interventricular Septum. JACC Cardiovasc Imaging. 2017;10(10 Pt B):1281-84.

14. van Mourik MJW, Zaat DJV, Smulders MW, Heijman J, Lumens J, Dokter JE, et al. Adding Speckle-Tracking Echocardiography to Visual Assessment of Systolic Wall Motion Abnormalities Improves the Detection of Myocardial Infarction. J Am Soc Echocardiogr. 2018;S0894-7317(18)30505-4.

15. Anwar AM. Global and segmental myocardial deformation by 2D speckle tracking compared to visual assessment. World J Cardiol. 2012;4(12):341-6.